US › Healthcare

aTyr Pharma, Inc. (ATYR)

US · Healthcare · Biotechnology

$6.35+5.31%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-10.3M

EPS

$-0.11

EPS estimate

$-0.15

EPS came in at -0.11 against a street estimate of -0.15 — a beat of 26.7%.

Key statistics

Market cap

$15.1M

Forward P/E

0.0

P/B

0.34

Book value

$19.90

EPS (TTM)

$-24.66

52-week high

$44.40

52-week low

$4.07

50-day MA

$12.31

200-day MA

$23.86

Beta

1.05

Analyst view

Analysts rate aTyr Pharma, Inc. a buy (4 buy, 5 hold, 0 sell out of 9) with an average price target of $114.29.

Shareholding

Insiders

0.30%

Institutions

35.20%

Largest institutional holders

Fund	Stake
Federated Hermes Inc	8.68%
Vanguard Capital Management, LLC	3.88%
Kalehua Capital Management LLC	3.65%
GSA Capital Partners LLP	3.52%
AQR Capital Management LLC	2.66%
FMR Inc	2.52%
BlackRock Inc	1.86%
Jane Street Group LLC	1.75%

Corporate actions

Action	Detail	Date
Split	1 : 40 effective Oct 29, 2026	2026-10-29
Split	1 : 40 effective Oct 28, 2026	2026-10-28

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for aTyr Pharma, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.